Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Opus Biological is a London-based healthcare company specializing in regenerative medicine and orthobiologics. The company focuses on providing advanced non-surgical treatments for musculoskeletal conditions, sports injuries, and chronic pain, utilizing autologous therapies such as Platelet-Rich Plasma (PRP), Bone Marrow Aspirate Concentrate (BMAC), and adipose-derived stem cells. Their clinical practice integrates cutting-edge biological treatments like Alpha-2-Macroglobulin (A2M) injections to inhibit proteases that cause cartilage breakdown. Opus Biological serves elite athletes and patients seeking alternatives to traditional orthopedic surgery through personalized regenerative protocols.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Opus Biological.